Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (91-100 of 148) with videos related to

Pageof 15
Sort By:
Haematologica|March 7, 2024
Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative casesFaiqa Farrukh, Maymona Abdelmagid, Abhishek Mangaonkar, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
British Journal of Haematology|August 4, 2021
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive casesKebede H Begna, Jaya Kittur, Jennifer Yui, et al.
British Journal of Haematology|May 5, 2023
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasmsMark Gurney, Ismahene Chekkaf, Anmol Baranwal, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Leukemia & Lymphoma|October 24, 2012
Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapyMing Y Lim, Aref Al-Kali, Aneel A Ashrani, et al.
American Journal of Hematology|September 27, 2024
PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosisAyalew Tefferi, Saubia Fathima, Ali Khalid A Alsugair, et al.
Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.
Blood Cancer Journal|March 3, 2021
Mayo Clinic experience with 1123 adults with acute myeloid leukemiaKebede H Begna, Walid Ali, Naseema Gangat, et al.
American Journal of Clinical Pathology|May 12, 2021
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 MutationsElise R Venable, Dong Chen, Constance P Chen, et al.
Pageof 15

Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
Haematologica|March 7, 2024
Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative casesFaiqa Farrukh, Maymona Abdelmagid, Abhishek Mangaonkar, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
British Journal of Haematology|August 4, 2021
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive casesKebede H Begna, Jaya Kittur, Jennifer Yui, et al.
British Journal of Haematology|May 5, 2023
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasmsMark Gurney, Ismahene Chekkaf, Anmol Baranwal, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Leukemia & Lymphoma|October 24, 2012
Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapyMing Y Lim, Aref Al-Kali, Aneel A Ashrani, et al.
American Journal of Hematology|September 27, 2024
PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosisAyalew Tefferi, Saubia Fathima, Ali Khalid A Alsugair, et al.
Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.
Blood Cancer Journal|March 3, 2021
Mayo Clinic experience with 1123 adults with acute myeloid leukemiaKebede H Begna, Walid Ali, Naseema Gangat, et al.
American Journal of Clinical Pathology|May 12, 2021
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 MutationsElise R Venable, Dong Chen, Constance P Chen, et al.
Pageof 15